openPR Logo
Press release

B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Analysis, Forecast till 2026

08-17-2018 04:52 PM CET | Health & Medicine

Press release from: Coherent Market Insights

B-cell Maturation Antigen (BCMA) Targeted Therapies Market -

The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA) targeted therapies market worldwide.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/190

Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. According to American Cancer Society, as of 2017, around 30,280 multiple myeloma cases are estimated to be diagnosed, out of which around 12,590 deaths are estimated to occur. Multiple myeloma (MM) is the second most common hematological malignancy in the U.S. and European countries. According to American Cancer Society, in the U.S. the lifetime risk of contracting multiple myeloma is 1 in 143 (0.7%). B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells.

Browse through 130 Pages and an in-depth TOC on ‘B-cell Maturation Antigen (BCMA) Targeted Therapies, by Product type (Antibody Drug Conjugates, CAR-T Cells, and Bispecific Antibodies), by Indication (Acute Lymphoblastic Leukemia and Multiple Myeloma), and by Region

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/190

According to the Cancer Research U.K., as of 2014, myeloma is estimated to be the 18th most common cancer in the U.K., with an estimated 5,500 new cases of multiple myeloma, reported around 15 new cases every day. Incidence rates for myeloma are projected to rise by 11% or 12 cases per 100,000 people by 2035. According to the National Center for Biotechnology Information, 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.

Market players are actively investing in research and development of novel multiple myeloma therapies to develop alternatives for existing drugs. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and bispecific antibodies. Preclinical and clinical trial results on these therapies have demonstrated potential benefits.

Key Takeaways of the Market:

According to the American Society of Clinical Oncology (ASCO), in 2016, multiple myeloma was the second most common blood cancer, after non-Hodgkin lymphoma, accounting for 1% of all kinds of malignancies globally, with 70 years being the median age of diagnosis

As there are no treatment option available for patients with recurrent cancer, development of therapy to treat relapsed and/or refractory multiple myeloma is expected to provide market players with lucrative opportunities

Some of the major players involved in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/190

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Analysis, Forecast till 2026 here

News-ID: 1186273 • Views:

More Releases from Coherent Market Insights

Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abbott Laboratories, Amway, Atkins, Blue Diamond Growers
Meal Replacement Market Market to Hit $22.01 Bn by 2032 with a CAGR of 5.8% |Abb …
The Meal Replacement Market is estimated to be valued at USD 14.82 Bn in 2025 and is expected to reach USD 22.01 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Meal Replacement Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends, key growth
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion by 2032 with a 7.9% CAGR |C&D Technologies Inc., Crown Battery Manufacturing Co., East Penn Manufacturing Co. Inc., EnerSys
Deep Cycle Battery Market, Market Outlook : Projected to Exceed USD 4.73 Billion …
The deep cycle battery market is estimated to be valued at USD 2.77 billion in 2025 and is expected to reach USD 4.73 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Deep Cycle Battery Market, Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by 2025-2032 |Hangzhou Xunda Packaging Co., Smurfit Kappa Group PLC, DS Smith Plc, Pregis Corporation
Consumer Electronics Packaging Market Market Projected to Witness Huge Growth by …
The consumer electronics packaging market is estimated to be valued at USD 26.57 Bn in 2025 and is expected to reach USD 81.72 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Consumer Electronics Packaging Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koninklijke DSM N.V., BAE Systems, Morgan Advanced Materials , Saint-Gobain S.A.
Ceramic Armor Market Market Set to Witness Significant Growth by 2025-2032 |Koni …
The global ceramic armor market is estimated to be valued at USD 2.75 Bn in 2025 and is expected to reach USD 4.08 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.8% from 2025 to 2032. The latest report from Coherent Market Insights examines the growth prospects of the Ceramic Armor Market Market from 2025 to 2032. This in-depth analysis covers industry size, market share, business trends,

All 5 Releases


More Releases for BCMA

BCMA-Targeted CAR-T Cell Therapy Market Poised for Robust Growth by 2033
London, UK - September 2025 | Strategic Revenue Insights Inc. The global BCMA-Targeted CAR-T Cell Therapy market is rapidly emerging as a transformative segment within oncology, redefining treatment paradigms for hematologic malignancies, particularly multiple myeloma. Valued for its personalized approach and precision targeting, BCMA-focused CAR-T therapies leverage a patient's immune system to combat cancer cells effectively. The growing incidence of multiple myeloma, coupled with advancements in CAR-T engineering, underscores the
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future. Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 2 Drugs * Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026 * Future Market Assessment By Indication Till 2026 *
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report | For …
B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for B-cell development and also in autoimmune response. This receptor specially binds to tumor necrosis factor (TNF)